Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year.
[More]
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors.
[More]
The team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program in the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, has identified epigenetic changes that occur in adult stem cells to generate different body tissues. The finding is published this week in The American Journal of Pathology.
[More]
Using a novel surgical approach, it's possible to rebuild a functional lower jaw and mouth, and preserve a patient's ability to eat and speak after removing an invasive facial tumor, according to a new report from Henry Ford Hospital in Detroit.
[More]
Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced that the first of two canine oncology products has received approval by regulators in both the U.S. and Canada.
[More]
The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.
[More]
Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.
[More]
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
[More]
In many families, women are the health care decision makers. When children go for their checkups, we are often the ones who make the appointment and sit in the room holding their hand. When elderly parents see a new specialist, we are the ones carrying the folder with all their health information. ... In the past, this also meant that many women would take care of their own health last. By the time they got around to it, women found a system stacked against them. But thanks to the health care law, that's changed.
[More]
The United States Food and Drugs Administration (FDA) have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been concerning patients and families particularly of the children with leukemia. But there are currently 283 separate prescription drugs in short supply or unavailable nationwide, and regulators and manufacturers say shortages are a long-term problem that will continue to scare patients and doctors.
[More]
A person has a tumor removed from her femur. A soldier is struck by an improvised explosive device and loses a portion of his tibia. A child undergoes chemotherapy for osteosarcoma but part of the bone dies as a result.
[More]
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.
[More]
A paper in the Journal of Dental Research by dentist Chester Douglass and colleagues, "An Assessment of Bone Fluoride and Osteosarcoma," claims to show no association between fluoride bone levels and osteosarcoma, a form of bone cancer.
[More]
A new study in the Journal of Dental Research finds bone fluoride levels are not associated with osteosarcoma, a rare bone cancer more prevalent in males.
[More]
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.
[More]
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
[More]
Synthes, Inc. and Eli Lilly and Company today announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.
[More]
Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell.
[More]
Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.
[More]
Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.
[More]